How is pramipexole dosed?
| Form | Strengths on the label |
|---|---|
| Immediate-release tablet | 0.125, 0.25, 0.5, 0.75, 1 and 1.5 mg1 |
| Extended-release tablet | 0.375 and 0.75 mg2 |
The US immediate-release label's Parkinson's disease schedule, in mg, runs from 0.125 three times a day in week 1 to 1.5 three times a day in week 7, and its restless legs syndrome studies gave 0.125 mg, 0.25 mg, 0.5 mg or 0.75 mg or placebo once daily 2-3 hours before going to bed.1
Tablet strengths
The table is set at the top of the page
The extended-release label says its tablets are indicated for Parkinson's disease, are taken orally once daily with or without food, and are swallowed whole, not chewed, crushed or divided.2 The immediate-release label says the tablets can be taken with or without food.1 A DailyMed search found tablets and extended-release tablets only, with no oral powder or oral solution.
Parkinson's disease: label dose and schedule
The immediate-release label's Parkinson's disease schedule limits increases to no more often than every 5-7 days.1 The label's suggested ascending schedule, in mg, runs week by week from 0.125 three times a day in week 1 to 1.5 three times a day in week 7.1
The extended-release label gives once-daily dosing from 0.375 mg, raised no more often than every 5 to 7 days, first to 0.75 mg per day and then in 0.75 mg steps up to a maximum of 4.5 mg per day.2
Restless legs syndrome: label dose and schedule
The label's 4 placebo-controlled RLS trials, with about 1000 patients with moderate to severe RLS, gave 0.125 mg, 0.25 mg, 0.5 mg or 0.75 mg or placebo once daily 2-3 hours before going to bed.1
Kidney problems and the dose
| Parkinson's disease, creatinine clearance (CrCl) | Start (mg) | Maximum (mg) |
|---|---|---|
| Above 50 mL/min | 0.125 three times a day1 | 1.5 three times a day1 |
| 30 to 50 mL/min | 0.125 twice a day1 | 0.75 three times a day1 |
| 15 to 30 mL/min | 0.125 once a day1 | 1.5 once a day1 |
At creatinine clearance between 30 and 50 mL/min, the extended-release label has the tablets initially taken every other day, with careful assessment before daily dosing after one week and before titration in 0.375 mg increments up to 2.25 mg per day, adjusted no more often than weekly.2 The extended-release label says its tablets have not been studied in severe renal impairment (creatinine clearance <30 mL/min) or in patients on hemodialysis, and are not recommended in these patients.2
Reducing or stopping
The extended-release label calls for gradual discontinuation and says the tablets may be tapered off at a rate of 0.75 mg per day until the daily dose is 0.75 mg, then reduced by 0.375 mg per day.2 The immediate-release label's patient information says not to stop the tablets without talking to a doctor first, and that dopamine agonists can cause withdrawal symptoms as the dose is lowered or when treatment is stopped.1
Doses used in named trials
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Parkinson Study Group, 1997 | 1.5, 3.0, 4.5 or 6.0 mg/d or placebo3 | 264, early Parkinson's disease, no levodopa or other dopamine agonists3 | 6 weeks escalation, 4 weeks maintenance, 1 week withdrawn3 |
| Barone, 2010 | 0.125-1.0 mg three times per day or placebo4 | 323 enrolled, 296 randomly assigned; mild-to-moderate Parkinson's disease, depressive symptoms4 | 12 weeks4 |
| Allen, 2014 | Pramipexole 0.25 mg or 0.5 mg per day or pregabalin 300 mg per day for 52 weeks, or 12 weeks of placebo then 40 weeks of active treatment5 | 719, RLS | 52 weeks |
| PRELUDE (Partinen), 2006 | Fixed doses within 0.125-0.75 mg/d or placebo6 | 109, moderate to severe RLS6 | 3 weeks6 |
| Winkelman, 2006 | Fixed 0.25, 0.50 or 0.75 mg/day or placebo, up-titrated over 3 weeks7 | 344, moderate to severe RLS7 | 12 weeks7 |
| NCT00390689 (2006) | Fixed 0.25, 0.5 or 0.75 mg once daily8 | 154, idiopathic RLS8 | 6 weeks double-blind, then 46 weeks open label8 |
| NCT00654498 (2008) | Titration from 0.125 mg through 0.25, 0.5 and 0.75 mg, then a fixed dose, once daily, or placebo9 | 306, idiopathic RLS out-patients9 | 4 weeks titration, 2 weeks fixed9 |
In the Allen trial of 719 people with RLS, augmentation over 40 or 52 weeks was 7.7% with pramipexole 0.5 mg and 5.3% with 0.25 mg, against 2.1% with pregabalin; the authors report the pregabalin rate as significantly lower than with 0.5 mg (P=0.001) but not than with 0.25 mg (P=0.08).5
Storage
The immediate-release label gives storage at 20°-25°C (68°-77°F), with excursions permitted to 15°-30°C, protected from light.1 The extended-release label gives 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F), and says to protect the tablets from exposure to high humidity.2
Frequently asked questions
Is pramipexole labelled for depression, anhedonia or prolactin?
The label's indications are Parkinson's disease and moderate-to-severe primary restless legs syndrome.1 The Stanford RAD-AT registry record (NCT02220309), an observational study of 167 people who had recently experienced symptoms of anxiety and/or depression, with no diagnosis required, gives a 12 week course of pramipexole or rTMS in its summary and 8 weeks of treatment in its detailed description, and gives no pramipexole dose.10 No saved source gives a dose for depression in people without Parkinson's disease, and searches of DailyMed, the trial registry and PubMed found no prolactin or anhedonia indication.
References
- Strides Pharma Science Limited via DailyMed (US label). These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS. PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997. 2025. dailymed.nlm.nih.gov
- Vitruvias Therapeutics, Inc. via DailyMed (US label). These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE EXTENDED-RELEASE TABLETS. PRAMIPEXOLE DIHYDROCHLORIDE extended-release tablets, for oral use. 2024. dailymed.nlm.nih.gov
- JAMA (PubMed abstract). Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. 1997. pubmed.ncbi.nlm.nih.gov
- The Lancet. Neurology (PubMed abstract). Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. 2010. pubmed.ncbi.nlm.nih.gov
- The New England journal of medicine (PubMed abstract). Comparison of pregabalin with pramipexole for restless legs syndrome. 2014. pubmed.ncbi.nlm.nih.gov
- Sleep medicine (PubMed abstract). Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study. 2006. pubmed.ncbi.nlm.nih.gov
- Neurology (PubMed abstract). Efficacy and safety of pramipexole in restless legs syndrome. 2006. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT00390689: A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS. 2009. clinicaltrials.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT00654498: Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS). 2010. clinicaltrials.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT02220309: Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment). 2025. clinicaltrials.gov